Afya Bora Consortium, Department of Global Health, University of Washington, Seattle, Washington, USA.
Division of Global HIV & TB (DGHT), Center for Global Health (CGH), US Centers for Disease Control and Prevention, Kisumu, Kenya.
J Int AIDS Soc. 2023 Mar;26(3):e26069. doi: 10.1002/jia2.26069.
In 2020, Kenya had 19,000 new HIV infections among women aged 15+ years. Studies have shown sub-optimal oral pre-exposure prophylaxis (PrEP) use among sub-populations of women. We assessed the uptake and continuation of oral PrEP among women 15-49 years in two health facilities in Kisumu County, Kenya.
A retrospective cohort of 262 women aged 15-49 years, initiated into oral PrEP between 12 November 2019 and 31 March 2021, was identified from two health facilities in the urban setting of Kisumu County, Kenya. Data on baseline characteristics and oral PrEP continuation at months 1, 3 and 6 were abstracted from patient records and summarized using descriptive statistics. Missing data in the predictor variables were imputed within the joint modelling multiple imputation framework. Using logistic regression, we evaluated factors associated with the discontinuation of oral PrEP at month 1.
Of the 66,054 women screened, 320 (0.5%) were eligible and 262 (82%) were initiated on oral PrEP. Uptake was higher among women 25-29 years as compared to those 15-24 years (77% vs. 33%). Oral PrEP continuation declined significantly with increasing duration of follow-up; 37% at month 1, 21% at month 3 and 12% at month 6 (p<0.05). In the adjusted analysis, women 15-24 years had lower adjusted odds of continuing at month 1 than women ≥25 years (adjusted odds ratio [aOR]: 0.41, 95% CI: 0.21-0.82). There was no association between being sero-discordant and continuation of oral PrEP at month 1 (aOR; 1.21, 95% CI 0.59-2.50). Women from the sub-county hospital were more likely to continue at month 1 of follow-up compared to women enrolled in the county referral hospital (aOR 5.11; 95% CI 2.24-11.70).
The low eligibility for oral PrEP observed among women 15-49 years in an urban setting with high HIV prevalence calls for a review of the screening process to validate the sensitivity of the screening tool and its proper application. The low uptake and continuation among adolescent girls and young women underscores the need to identify and address specific patient- and facility-level barriers affecting different sub-populations at risk for HIV acquisition.
2020 年,肯尼亚有 19000 名 15 岁以上女性新感染艾滋病毒。研究表明,部分女性人群中口服暴露前预防(PrEP)的使用并不理想。我们评估了肯尼亚基苏木县两个卫生机构中 15-49 岁女性对口服 PrEP 的使用情况。
我们从肯尼亚基苏木县城区的两个卫生机构中确定了 262 名年龄在 15-49 岁之间、于 2019 年 11 月 12 日至 2021 年 3 月 31 日期间开始使用口服 PrEP 的女性,建立了一个回顾性队列。从患者记录中提取了基线特征和口服 PrEP 在第 1、3 和 6 个月的延续数据,并使用描述性统计进行了总结。在联合建模多重插补框架内对预测变量中的缺失数据进行了插补。使用逻辑回归评估了与第 1 个月停用口服 PrEP 相关的因素。
在筛查的 66054 名女性中,有 320 名(0.5%)符合条件,有 262 名(82%)开始使用口服 PrEP。25-29 岁的女性与 15-24 岁的女性相比,口服 PrEP 的使用率更高(77%对 33%)。随着随访时间的延长,口服 PrEP 的持续率显著下降;第 1 个月为 37%,第 3 个月为 21%,第 6 个月为 12%(p<0.05)。在调整分析中,与≥25 岁的女性相比,15-24 岁的女性继续使用口服 PrEP 的调整后比值比(aOR)较低(0.41,95%置信区间:0.21-0.82)。血清不一致与第 1 个月继续使用口服 PrEP 之间无关联(aOR;1.21,95%CI 0.59-2.50)。与在县转诊医院登记的女性相比,在县医院登记的女性在第 1 个月的随访中更有可能继续使用(aOR 5.11;95%CI 2.24-11.70)。
在 HIV 流行率较高的城区环境中,观察到 15-49 岁女性口服 PrEP 的资格较低,这需要对筛选过程进行审查,以验证筛选工具的敏感性及其正确应用。在青少年女孩和年轻女性中,口服 PrEP 的使用率和持续率较低,这突显了需要确定和解决影响不同高危亚人群的具体患者和机构层面的障碍。